Table 2. The susceptible tissue/subtissue and cancer type associated with the TSGs and POGs identified for analysis, plus the expression of these genes in susceptible vs nonsusceptible tissues.

Gene type	Gene	High-penetrance cancer	Susceptible tissue type	Kruskal–Wallis test P-value	Expression (susc. tissue)	Expression (other tissues)	Significance category	Relative expression	Susceptible subtissue	Rel. expr. in susc. subtissue	Subtissue significance category
Tumour suppressor genes	ATM	Leukaemia, lymphoma	Immune system	5.06E−15	2.886±0.472	−0.028±0.206	A (2)	7.54	Lymph node	11.68	A (1)
	STK11	gastrointestinal polyps	Gastrointestinal	5.06E−15	1.814±0.173	0.108±0.224	A (2)	3.26	Small intestine	3.34	A (3)
	NF1	Glioma, other CNS cancers	Brain and nerve	5.06E−15	0.645±0.076	−0.432±0.205	A (1)	2.11	NA
	RB1	Osteosarcoma	Bone	5.06E−15	0.62±0.203	−0.060±0.123	A (2)	1.60	NA
	SMAD4	Gastrointestinal polyps	Gastrointestinal	1.29E−03	0.878±0.324	0.260±0.106	A (2)	1.53	Small intestine	2.21	A (1)
	CDKN2A	Melanoma	Skin	2.99E−07	0.904±0.510	0.386±0.389	B	1.43	Epidermis	0.41	E
	MEN1	Parathyroid adenoma	Endocrine	5.06E−15	−0.246±0.139	−0.758±0.249	B	1.43	Thyrocyte	1.26	A (7)
	BRCA2	Prostate	Male reproductive	1.17E−10	0.106±0.190	−0.237±0.194	BC	1.27	Prostate gland	1.01	A (6)
	PRKAR1A	Myxoma	Heart and muscle	5.06E−15	0.655±0.099	0.015±0.331	BC	1.56	Heart	2.36	A (2)
	PHOX2B	Neuroblastoma	Brain and nerve	2.02E−12	−0.066±0.067	0.134±0.203	BC	0.87	NA
	PTCH1	Skin basal cell	Skin	5.06E−15	−0.069±0.116	0.136±0.156	BC	0.69	Keratinocyte	0.86	BC
	MLH1	Endometrial	Female reproductive	5.06E−15	−0.211±0.088	−0.387±0.190	CD	1.13	Placenta basal plate	1.19	CD
	BRCA1	Ovarian	Female reproductive	5.06E−15	−0.779±0.070	−0.394±0.173	CDE	0.77	Ovary	0.77	DE
	TP53	Osteosarcoma	Bone	5.06E−15	−0.378±0.045	−0.222±0.172	D	0.90	NA
	MSH2	Ovarian	Female reproductive	5.06E−15	−0.807±0.081	−0.487±0.157	DE	0.80	Ovary	1.67	A (3)
	PRKAR1A	Testicular	Male reproductive	5.06E−15	−0.198±0.260	0.093±0.335	EF	0.82	NA
				TSG average:	0.368±0.254	−0.130±0.082
Proto-oncogenes	RET	Medullary thyroid	Endocrine	1.40E−11	7.097±2.437	0.158±0.164	A (3)	122.77	NA
	TSHR	Thyroid adenoma	Endocrine	7.13E−03	6.588±4.292	0.868±0.399	A (1)	52.72	NA
	MPL	Myeloproliferative disorder	Bone	1.08E−12	2.594±0.598	0.519±0.211	A (1)	4.21	NA
	ALK	Neuroblastoma	Brain and nerve	5.06E−15	0.697±0.065	−0.261±0.108	A (1)	1.94	NA
	EGFR	Non-small-cell lung cancer	Epithelium	5.06E−15	0.473±0.056	0.112±0.186	A (5)	1.28	NA
	LMO1	Neuroblastoma	Brain and nerve	7.59E−07	0.179±0.076	0.106±0.140	ABCD	1.05	NA
	KIT	Gastrointestinal stromal tumour	Gastrointestinal	5.06E−15	1.053±0.255	1.062±0.138	CD	0.99	Small intestine	0.79	CD
	HRAS	Rhabdomyosarcoma	Heart and muscle	5.06E−15	−0.743±0.089	−0.76±0.329	DE	1.01	Skeletal muscle	1.6	C
				POG average:	2.24±1.06	0.225±0.209

Abbreviations: CNS= central nervous system; NA=not applicable; POG=proto-oncogene; Rel. expr.=relative expression; susc.=susceptible; TSG=tumour suppressor gene.

For each gene, results are shown for the Kruskal–Wallis test across the 12 broad tissue categories (P-value=significance after Bonferroni correction) and the significance categories assigned to the susceptible tissue in the subsequent Kruskal–Wallis multiple comparison test. For genes in significance category ‘A', the total number of tissues tied in that category is given in parentheses. Also shown are the log₂ expression (±1 s.e.) of each gene in the susceptible tissue type, the mean for the 11 other tissues and the ratio of these expression levels. For those genes that could also be analysed at the level of subtissue, the results from the subtissue analysis are also shown.